Dawn P. Edwards
Wellness Ambassador
The Rogosin Institute
CEO, NYS CKD Champions Forum of ESRD Networks
Co-Chairperson
Kidney Patient Advisory Council
Vineeta Kumar, M.D.
Professor of Medicine
The University of Alabama at Birmingham
Jeffrey Perl, M.D., SM, FRCP (C)
Staff Nephrologist
St. Michael’s Hospital
Associate Professor of Medicine
University of Toronto, Canada
Jeffrey Silberzweig, M.D.
Chief Medical Officer
The Rogosin Institute
Associate Professor of Clinical Medicine
Weill Cornell Medicine
Disclosures: Dr. Jeffrey Silberzweig - no financial relationships to disclose
Dr. Vineeta Kumar - no financial relationships to disclose
Ms. Dawn Edwards – no financial relationships to disclose
Dr. Jeffrey Perl – On the Speaker’s Bureau for Baxter; Consultant for Otsuka, GSK, LiberDi, Bayer; Receives Travel/ Stock Option from LiberDi
Moderators:
Jeffrey Silberzweig, M.D.
Objectives:
Target Audience: physicians, residents, students, PAs, NPs, nurses and other healthcare professionals
• Understand the benefits of home dialysis and transplantation as treatments for kidney failure.
• Recognize gaps in my practice for offering various treatment modalities to all patients.
• Develop tools to improve rates of patients choosing home dialysis.
• Understand the role of patients in advocating for each other.
Accreditation
NewYork Presbyterian/Queens is accredited by the Medical Society of the State of New York (MSSNY) to provide continuing medical education for physicians.
NewYork Presbyterian/Queens designates this Live Activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
The Medical Society of The State of New York relies upon planners and faculty participants in its CME activities to provide educational information that is objective and free of bias. In this spirit and in accordance with the guidelines of MSSNY, CPME and the ACCME, all speakers and planners for CME activities must disclose any relevant financial relationships with
commercial interests whose products, devices or services may be discussed in the content of a CME activity, that might be perceived as a real or apparent conflict of interest. Any discussion of investigational or unlabeled uses of a product will be identified.